Springworks Therapeutics Inc's ROI from its first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Springworks Therapeutics Inc's ROI in the first quarter of 2025?
Springworks Therapeutics Inc recorded a cumulative net loss of $-254 million during 12 months ending in the first quarter of 2025, resulting in a negative return on investment (ROI) of -50.5%.

Within the Healthcare sector Springworks Therapeutics Inc achieved the highest return on investment. While the total ranking for ROI remained the same, compared to the fourth quarter of 2024 at no. .

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Investment Change TTM	-5.49 %	5.04 %	16.57 %	-0.16 %	2.58 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	423	487	538	563	588
Return On Investment (TTM)	-50.5 %	-47.44 %	-47.1 %	-54.35 %	-63.73 %
SWTX's Overall Ranking	#	#	#	#	#
Seq. Investment Change TTM	-7.57 %	-6.86 %	5.46 %	4.11 %	2.73 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-254	-258	-275	-301	-339

SWTX Company Profile >> Back to SWTX Roi Comparisons >> See Annual SWTX Return On Investment

Return On Investment SWTX's Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Investment Statistics
High	Average	Low
0 %	0 %	0 %

News about Springworks Therapeutics Inc Return on Investment ROI

SpringWorks Therapeutics Unveils Promising Long-Term Findings for OGSIVEO in Desmoid Tumors at 2024 CTOS Annual Meeting

November 7, 2024

As the field of oncology continues to advance, the importance of long-term efficacy and safety data remains paramount in the development of novel therapeutics. SpringWorks Therapeutics Inc. (NASDAQ: SWTX) has made significant strides in this arena, announcing compelling findings from its Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in adults diagnosed with desmoid tumors, which are notoriously challenging to manage due to their unpredictable nature and potential for aggressive behavior. Scheduled for presentation at the upcoming Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting, the long-term follow-up data from the DeFi Trial brings forth a wealth of information. The results reveal not only sustained improvements in patient outcomes but also an impressive long-term safety profile for OGSIVEO. Data indicate that patients experienced a substantial reduction in tumor size, with an increased overall response rate (ORR) highlighted by additional complete responses (CRs). This is a pivotal finding for patients who have long searched for effective treatment options for these tumors, which often lead to significant morbidity and, in some cases, mortality. Beyond tumor size reduction, the long-term follow-up showed a sustained improvement in desmoid tumor symptoms, which is critical in improving the quality of life for patients who endure these often painful and debilitating tumors.Equally important is the established safety profile of OGSIVEO over time, with a median duration of therapy stretching to approximately three years. This durability of treatment underscores the potential of nirgacestat to offer not only efficacy but also safety a crucial consideration when selecting treatment options for patients with chronic conditions such as desmoid tumors.

Financial Statements
Springworks Therapeutics Inc's I. Quarter Investments	$ 423 Millions	SWTX's Balance sheet
Springworks Therapeutics Inc's I. Quarter Income	$ -83 Millions	Quarterly SWTX's Income Statement
SWTX's Income by Division		See SWTX's Income by Division

SWTX Annual Return On Investment	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021	(Dec 31 2020) 2020
Total Investments in Millions	487	648	579	423	559
Y / Y Investment Growth	-24.76 %	11.81 %	37.08 %	-24.36 %	73.01 %
Net Income in Millions	-258	-325	-277	-174	-46
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-52.97 %	-50.2 %	-47.9 %	-41.16 %	-8.16 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SWTX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SWTX's Competitors
Subscribers only: Roi for Springworks Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for SWTX's Customers

Other Ratios
SWTX's Roa	SWTX's Inventory Turnover Ratio	SWTX's Growth Rates	SWTX's Dividend Statistics
	SWTX's Profitability Ratios	SWTX's Asset Turnover Ratio	SWTX's Dividend Growth
SWTX's Roe	SWTX's Valuation Ratios	SWTX's Financial Strength Ratios	SWTX's Dividend Payout Ratio

Companies with similar Return On Investment at Mar 31 2025, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:37:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.